73 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
23 Jun 23
2023 Annual General Meeting of Shareholders
4:15pm
is deducted for the manager’s insurance policy and 2-1/2% is deducted for the study fund. Mr. Farbstein is also entitled to reimbursement for reasonable out
D
CANF
Can-Fite Biopharma Ltd
30 Dec 21
$10M in options / securities to be acquired, sold $10M, 1 investor
4:15pm
is also entitled to non-accountable expense reimbursement of $75,000 and warrants to purchase an aggregate of 350,000 ADSs exercisable at $2.00 per ADS
6-K
EX-10.1
3ybpw
16 Aug 21
Report of Foreign Private Issuer
10:21am
6-K
EX-10.1
uunn4tynifyb1i 4zpob
8 Jul 20
Report of Foreign Private Issuer
10:39am
6-K
EX-10.1
547 oopgo6bzy
12 Jun 20
Report of Foreign Private Issuer
8:03am
424B3
com27
1 Jun 20
Prospectus supplement
7:23am
6-K
EX-99.2
rxxiaqw
1 Jun 20
Report of Foreign Private Issuer
7:06am
6-K
EX-99.1
7h0rfvlq92g0yim6y
1 Jun 20
Report of Foreign Private Issuer
7:06am
6-K
EX-99.1
v4xt8bt8zc5gk5
13 Feb 20
Notice of Special General Meeting of Shareholders
4:30pm
6-K
2b6 iikcsskh
12 Feb 20
Report of Foreign Private Issuer
4:31pm
6-K
EX-10.1
cbq3h
12 Feb 20
Report of Foreign Private Issuer
4:31pm
424B4
j9dyf3q5rpt2d
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
uy412iwj2qga
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1/A
EX-10.32
wu194 r5h
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
ggg8m ku2m3l0
24 Jan 20
Registration statement (foreign)
4:40pm